Veracyte, Inc.
VCYT
Rang în acțiuni
#4437
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Preț acțiune
$43.73
Capitalizare de piață
$3.52B
Schimbare (1 zi)
1.40%
Schimbare (1 an)
22.03%
Țară
US
Tranzacționează Veracyte, Inc. (VCYT)
Categorie
Healthcare
EPS pentru Veracyte, Inc. (VCYT)
EPS la data de June 2026 TTM: $1.44
Conform celor mai recente rapoarte financiare și prețului acțiunilor Veracyte, Inc., EPS-ul actual al companiei (TTM) este $1.44. La sfârșitul anului 2023, compania avea un EPS de $-1.02 o creștere față de EPS-ului din 2022, care a fost de $-0.51.
Istoricul EPS pentru Veracyte, Inc. din 2011 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $1.44 | 350.00% |
| 2024 | $0.32 | -131.37% |
| 2023 | $-1.02 | 100.00% |
| 2022 | $-0.51 | -54.05% |
| 2021 | $-1.11 | 68.18% |
| 2020 | $-0.66 | 144.44% |
| 2019 | $-0.27 | -56.45% |
| 2018 | $-0.62 | -31.87% |
| 2017 | $-0.91 | -16.51% |
| 2016 | $-1.09 | -16.15% |
| 2015 | $-1.30 | -4.41% |
| 2014 | $-1.36 | -77.89% |
| 2013 | $-6.15 | 369.47% |
| 2012 | $-1.31 | 28.43% |
| 2011 | $-1.02 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $18.62 | 1,193.06% |
US
|
|
| $5.65 | 292.36% |
US
|
|
| $-1.36 | -194.44% |
US
|
|
| - | - |
CN
|
|
| $5.09 | 253.47% |
US
|
